Fasudil, a Rho kinase inhibitor, attenuates cardiovascular changes in an experimental rat model of metabolic syndrome via modulation of PCSK9 and BNP.
Shamardl, H., Nageeb, S., Sadik, S., Helal, A., Shabana, M. (2024). Fasudil, a Rho kinase inhibitor, attenuates cardiovascular changes in an experimental rat model of metabolic syndrome via modulation of PCSK9 and BNP.. EKB Journal Management System, 13(2), 99-110. doi: 10.21608/fumj.2024.259818.1309
Hanan Shamardl; Samar Nageeb; Sawsan A. Sadik; Ayman Helal; Mona Shabana. "Fasudil, a Rho kinase inhibitor, attenuates cardiovascular changes in an experimental rat model of metabolic syndrome via modulation of PCSK9 and BNP.". EKB Journal Management System, 13, 2, 2024, 99-110. doi: 10.21608/fumj.2024.259818.1309
Shamardl, H., Nageeb, S., Sadik, S., Helal, A., Shabana, M. (2024). 'Fasudil, a Rho kinase inhibitor, attenuates cardiovascular changes in an experimental rat model of metabolic syndrome via modulation of PCSK9 and BNP.', EKB Journal Management System, 13(2), pp. 99-110. doi: 10.21608/fumj.2024.259818.1309
Shamardl, H., Nageeb, S., Sadik, S., Helal, A., Shabana, M. Fasudil, a Rho kinase inhibitor, attenuates cardiovascular changes in an experimental rat model of metabolic syndrome via modulation of PCSK9 and BNP.. EKB Journal Management System, 2024; 13(2): 99-110. doi: 10.21608/fumj.2024.259818.1309

Fasudil, a Rho kinase inhibitor, attenuates cardiovascular changes in an experimental rat model of metabolic syndrome via modulation of PCSK9 and BNP.

Fayoum University Medical Journal
Volume 13, Issue 2, April 2024, Page 99-110  XML PDF (455.04 K)
Document Type: Full Length research Papers
DOI: 10.21608/fumj.2024.259818.1309
View on SCiNiTO View on SCiNiTO
Authors
Hanan Shamardl* 1; Samar Nageeb2; Sawsan A. Sadik3; Ayman Helal2; Mona Shabanaorcid 4
1Medical pharmacology, Faculty of Medicine, Fayoum University
2Medical Pharmacology , Faculty of Medicine , Fayoum University
3Medical Pharmacology, Faculty of Medicine, Fayoum University
4Medical Pharmacology , Faculty of Medicine , Fayoum University- Egypt
Abstract
OBJECTIVE Metabolic syndrome (MS) is an important cardiovascular risk factor. Rho-kinase(ROCK) is a novel cardiovascular therapeutic target and its activity is increased in patients with MS.The study’s objective was to investigate the impact of fausdil, a Rho kinase inhibitor, on the Rho-ROCK pathway , nitric oxide (NO), brain natriuretic peptide(BNP) and cardiac PCSK9/LDL concentrations, and to explore its potential role in improving insulin resistance and cardiovascular abnormalities.
Materials and methods: 24 adult male Wistar albino rats were used and divided into 4 groups: Control, Fasudil1(10 mg/kg/day subcutaneously), Sucrose-fed(30% in drinking water), Sucrose+Fasudil group. daily for 3 weeks. Blood pressure and heart rate, serum biomarkers ( ROCK1, BNP, NO, insulin, glucose and LDL-c ) , and cardiac PCSK-9 concentrations were assessed in addition to cardiac histopathology.

Results: The data proved that sucrose +fasudil treatment significantly ameliorated the levels of systolic blood pressure, glycemic indices, serum LDL, Rho kinase, NO, and BNP and cardiac PCSK9 compared to the untreated sucrose group. Histology examination confirmed the positive impact of fasudil on cardiac inflammation, fibrosis and tissue degeneration compared to the untreated.
Conclusion: Fasudil has a cardioprotective effects with improved glycemic indices on sucrose-induced MS in rats. By its action not only on RhoA/Rho kinase (ROCK) signaling pathway but also on BNP, NO, and cardiac PCSK9 modulation activity. The study provided a promise to use fasudil clinically in MS beyond RhoA/ROCK inhibtiton.
Keywords
Sucrose; Fasudil; Rho kinase; PCSK9
Statistics
Article View: 48
PDF Download: 45